Skip to main content
Erschienen in: Journal of General Internal Medicine 11/2019

05.08.2019 | Original Research

Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study

verfasst von: Oguzhan Alagoz, PhD, Ali Hajjar, MS, Sarocha Chootipongchaivat, MS, Nicolien T. van Ravesteyn, PhD, Jennifer M. Yeh, PhD, Mehmet Ali Ergun, PhD, Harry J. de Koning, MD, PhD, Brian Chicoine, MD, Barry Martin, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

ABSTRACT

Background

Women with Down syndrome have a lower breast cancer risk and significantly lower life expectancies than women without Down syndrome. Therefore, it is not clear whether mammography screening strategies used for women without Down syndrome would benefit women with Down syndrome in the same way.

Objective

To determine the benefits and harms of various mammography screening strategies for women with Down syndrome using collaborative simulation modeling.

Design

Two established Cancer Intervention and Surveillance Modeling Network (CISNET) simulation models estimated the benefits and harms of various screening strategies for women with Down syndrome over a lifetime horizon.

Participants

We modeled a hypothetical cohort of US women with Down syndrome who were born in 1970.

Interventions

Annual, biennial, triennial, and one-time digital mammography screenings during the ages 40–74.

Main Measures

The models estimated numbers of mammograms, false-positives, benign biopsies, breast cancer deaths prevented, and life-years gained per 1000 screened women when compared with no screening.

Key Results

In average-risk women 50–74, biennial screening incurred 122 mammograms, 10 false-positive mammograms, and 1.4 benign biopsies per one life-year gained compared with no screening. In women with Down syndrome, the same screening strategy incurred 2752 mammograms, 242 false-positive mammograms, and 34 benign biopsies per one life-year gained compared with no screening. The harm/benefit ratio varied for other screening strategies, and was most favorable for one-time screening at age 50, which incurred 1629 mammograms, 144 false-positive mammograms, and 20 benign biopsies per one life-year gained compared with no screening.

Conclusions

The harm/benefit ratios for various mammography screening strategies in women with Down syndrome are not as favorable as those for average-risk women. The benefit of screening mammography for women with Down syndrome is less pronounced due to lower breast cancer risk and shorter life expectancy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, et al. Benefits and harms of breast cancer screening: a systematic review. Jama. 2015;314(15):1615–34.CrossRef Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, et al. Benefits and harms of breast cancer screening: a systematic review. Jama. 2015;314(15):1615–34.CrossRef
2.
Zurück zum Zitat Siu AL. Screening for breast cancer: US preventive services task force recommendation StatementScreening for breast cancer. Ann Intern Med. 2016;164(4):279–96.CrossRef Siu AL. Screening for breast cancer: US preventive services task force recommendation StatementScreening for breast cancer. Ann Intern Med. 2016;164(4):279–96.CrossRef
3.
Zurück zum Zitat de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in the United States. Genet Med. 2016;19(4):439–47.CrossRef de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in the United States. Genet Med. 2016;19(4):439–47.CrossRef
4.
Zurück zum Zitat Yang Q, Rasmussen SA, Friedman J. Mortality associated with Down’s syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002;359(9311):1019–25.CrossRef Yang Q, Rasmussen SA, Friedman J. Mortality associated with Down’s syndrome in the USA from 1983 to 1997: a population-based study. Lancet. 2002;359(9311):1019–25.CrossRef
5.
Zurück zum Zitat Glasson E, Sullivan S, Hussain R, Petterson B, Montgomery P, Bittles A. The changing survival profile of people with Down’s syndrome: implications for genetic counselling. Clin Genet. 2002;62(5):390–3.CrossRef Glasson E, Sullivan S, Hussain R, Petterson B, Montgomery P, Bittles A. The changing survival profile of people with Down’s syndrome: implications for genetic counselling. Clin Genet. 2002;62(5):390–3.CrossRef
6.
Zurück zum Zitat Zhu JL, Hasle H, Correa A, Schendel D, Friedman J, Olsen J, et al. Survival among people with Down syndrome: a nationwide population-based study in Denmark. Genet Med. 2012;15(1):64–9.CrossRef Zhu JL, Hasle H, Correa A, Schendel D, Friedman J, Olsen J, et al. Survival among people with Down syndrome: a nationwide population-based study in Denmark. Genet Med. 2012;15(1):64–9.CrossRef
7.
Zurück zum Zitat Englund A, Jonsson B, Zander CS, Gustafsson J, Annerén G. Changes in mortality and causes of death in the Swedish Down syndrome population. Am J Med Genet A. 2013;161(4):642–9.CrossRef Englund A, Jonsson B, Zander CS, Gustafsson J, Annerén G. Changes in mortality and causes of death in the Swedish Down syndrome population. Am J Med Genet A. 2013;161(4):642–9.CrossRef
8.
Zurück zum Zitat Satgé D, Sasco AJ. Breast screening guidelines should be adapted in Down’s syndrome. BMJ: Br Med J. 2002;324(7346):1155.CrossRef Satgé D, Sasco AJ. Breast screening guidelines should be adapted in Down’s syndrome. BMJ: Br Med J. 2002;324(7346):1155.CrossRef
9.
Zurück zum Zitat Hill DA, Gridley G, Cnattingius S, Mellemkjaer L, Linet M, Adami H-O, et al. Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med. 2003;163(6):705–11.CrossRef Hill DA, Gridley G, Cnattingius S, Mellemkjaer L, Linet M, Adami H-O, et al. Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med. 2003;163(6):705–11.CrossRef
10.
Zurück zum Zitat Patja K, Pukkala E, Sund R, Iivanainen M, Kaski M. Cancer incidence of persons with down syndrome in Finland: a population-based study. Int J Cancer. 2006;118(7):1769–72.CrossRef Patja K, Pukkala E, Sund R, Iivanainen M, Kaski M. Cancer incidence of persons with down syndrome in Finland: a population-based study. Int J Cancer. 2006;118(7):1769–72.CrossRef
11.
Zurück zum Zitat Hasle H, Friedman JM, Olsen JH, Rasmussen SA. Low risk of solid tumors in persons with Down syndrome. Genet Med. 2016. Hasle H, Friedman JM, Olsen JH, Rasmussen SA. Low risk of solid tumors in persons with Down syndrome. Genet Med. 2016.
12.
Zurück zum Zitat Al-Biltagi M. Chapter: Anesthesia in Down Syndrome Children. Down Syndrome Children-An Update. Bentham Science Publishers; 2015. Al-Biltagi M. Chapter: Anesthesia in Down Syndrome Children. Down Syndrome Children-An Update. Bentham Science Publishers; 2015.
13.
Zurück zum Zitat Bhattarai B, Kulkarni AH, Rao ST, Mairpadi A. Anesthetic consideration in downs syndrome--a review. 2008. Bhattarai B, Kulkarni AH, Rao ST, Mairpadi A. Anesthetic consideration in downs syndrome--a review. 2008.
14.
Zurück zum Zitat Borland LM, Colligan J, Brandom BW. Frequency of anesthesia-related complications in children with Down syndrome under general anesthesia for noncardiac procedures. Pediatr Anesth. 2004;14(9):733–8.CrossRef Borland LM, Colligan J, Brandom BW. Frequency of anesthesia-related complications in children with Down syndrome under general anesthesia for noncardiac procedures. Pediatr Anesth. 2004;14(9):733–8.CrossRef
15.
Zurück zum Zitat Meitzner MC, Skurnowicz JA. Anesthetic considerations for patients with Down syndrome. AANA J. 2005;73(2). Meitzner MC, Skurnowicz JA. Anesthetic considerations for patients with Down syndrome. AANA J. 2005;73(2).
16.
Zurück zum Zitat Butler MG, Hayes BG, Hathaway MM, Begleiter ML. Specific genetic diseases at risk for sedation/anesthesia complications. Anesth Analg. 2000;91(4):837–55.CrossRef Butler MG, Hayes BG, Hathaway MM, Begleiter ML. Specific genetic diseases at risk for sedation/anesthesia complications. Anesth Analg. 2000;91(4):837–55.CrossRef
17.
Zurück zum Zitat Satge D, Sasco A, Pujol H, Rethore M. Breast cancer in women with trisomy 21. Bull Acad Natl Med. 2001;185(7):1239–52; discussion 52-4.PubMed Satge D, Sasco A, Pujol H, Rethore M. Breast cancer in women with trisomy 21. Bull Acad Natl Med. 2001;185(7):1239–52; discussion 52-4.PubMed
18.
Zurück zum Zitat Chicoine B, Roth M, Chicoine L, Sulo S. Breast cancer screening for women with Down syndrome: Lessons learned. Intellect Dev Disabil. 2015;53(2):91–9.CrossRef Chicoine B, Roth M, Chicoine L, Sulo S. Breast cancer screening for women with Down syndrome: Lessons learned. Intellect Dev Disabil. 2015;53(2):91–9.CrossRef
19.
Zurück zum Zitat Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738–47.CrossRef Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738–47.CrossRef
20.
Zurück zum Zitat Mandelblatt JS, Stout NK, Schechter CB, Van Den Broek JJ, Miglioretti DL, Krapcho M, et al. Collaborative modeling of the benefits and harms associated with different US breast cancer screening strategies. Ann Intern Med. 2016;164(4):215–25.CrossRef Mandelblatt JS, Stout NK, Schechter CB, Van Den Broek JJ, Miglioretti DL, Krapcho M, et al. Collaborative modeling of the benefits and harms associated with different US breast cancer screening strategies. Ann Intern Med. 2016;164(4):215–25.CrossRef
23.
Zurück zum Zitat van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning H. Estimating the effects of risk-based screening and adjuvant treatment using the MISCAN-Fadia continuous tumor growth model for breast cancer. Med Decis Mak. 2017;In Press. van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning H. Estimating the effects of risk-based screening and adjuvant treatment using the MISCAN-Fadia continuous tumor growth model for breast cancer. Med Decis Mak. 2017;In Press.
24.
Zurück zum Zitat Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, et al. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 2015;162(3):157–66.CrossRef Sprague BL, Stout NK, Schechter C, van Ravesteyn NT, Cevik M, Alagoz O, et al. Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med. 2015;162(3):157–66.CrossRef
25.
Zurück zum Zitat Van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, et al. Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. J Natl Cancer Inst. 2015;107(7):djv103.CrossRef Van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, et al. Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. J Natl Cancer Inst. 2015;107(7):djv103.CrossRef
26.
Zurück zum Zitat Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, et al. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014;106(6):dju092.CrossRef Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, et al. Benefits, harms, and costs for breast cancer screening after US implementation of digital mammography. J Natl Cancer Inst. 2014;106(6):dju092.CrossRef
27.
Zurück zum Zitat Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA. 2018;319(2):154–64.CrossRef Plevritis SK, Munoz D, Kurian AW, Stout NK, Alagoz O, Near AM, et al. Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012. JAMA. 2018;319(2):154–64.CrossRef
28.
Zurück zum Zitat Glasson E, Sullivan S, Hussain R, Petterson B, Montgomery P, Bittles A. Comparative survival advantage of males with Down syndrome. Am J Hum Biol. 2003;15(2):192–5.CrossRef Glasson E, Sullivan S, Hussain R, Petterson B, Montgomery P, Bittles A. Comparative survival advantage of males with Down syndrome. Am J Hum Biol. 2003;15(2):192–5.CrossRef
29.
Zurück zum Zitat Day SM, Strauss DJ, Shavelle RM, Reynolds RJ. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol. 2005;47(3):171–6.CrossRef Day SM, Strauss DJ, Shavelle RM, Reynolds RJ. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol. 2005;47(3):171–6.CrossRef
30.
Zurück zum Zitat Torr J, Strydom A, Patti P, Jokinen N. Aging in Down syndrome: Morbidity and mortality. J Pol Pract Intell Disabil. 2010;7(1):70–81.CrossRef Torr J, Strydom A, Patti P, Jokinen N. Aging in Down syndrome: Morbidity and mortality. J Pol Pract Intell Disabil. 2010;7(1):70–81.CrossRef
31.
Zurück zum Zitat Satgé D, Kempf E, Dubois J-B, Nishi M, Trédaniel J. Challenges in Diagnosis and Treatment of Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge. Lung Cancer Int. 2016;2016. Satgé D, Kempf E, Dubois J-B, Nishi M, Trédaniel J. Challenges in Diagnosis and Treatment of Lung Cancer in People with Intellectual Disabilities: Current State of Knowledge. Lung Cancer Int. 2016;2016.
32.
Zurück zum Zitat Miller J, Ding L, Spaeth J, Lam J, Paquin J, Lin E, et al. Sedation methods for transthoracic echocardiography in children with Trisomy 21—a retrospective study. Pediatr Anesth. 2017;27(5):531–9.CrossRef Miller J, Ding L, Spaeth J, Lam J, Paquin J, Lin E, et al. Sedation methods for transthoracic echocardiography in children with Trisomy 21—a retrospective study. Pediatr Anesth. 2017;27(5):531–9.CrossRef
33.
Zurück zum Zitat Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778–86.CrossRef Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380(9855):1778–86.CrossRef
Metadaten
Titel
Benefits and Harms of Mammography Screening for Women With Down Syndrome: a Collaborative Modeling Study
verfasst von
Oguzhan Alagoz, PhD
Ali Hajjar, MS
Sarocha Chootipongchaivat, MS
Nicolien T. van Ravesteyn, PhD
Jennifer M. Yeh, PhD
Mehmet Ali Ergun, PhD
Harry J. de Koning, MD, PhD
Brian Chicoine, MD
Barry Martin, MD
Publikationsdatum
05.08.2019
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 11/2019
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05182-5

Weitere Artikel der Ausgabe 11/2019

Journal of General Internal Medicine 11/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.